Cysal was founded in June 2012 as a spin-off of the Institute of Molecular Microbiology and Biotechnology of the Westfälische Wilhelms-University in Münster. Cysal is active in the fields of biopolymers, peptides and especially dipeptides, it is in the start-up phase and has good VC funding, an innovative team, as well as a solid and fast growing network.
Cysal produces arginine-aspartate and lysine-aspartate dipeptides with an innovative process on an industrial scale for use in the food, cosmetics, pharmaceutical and feed industries. Even before its foundation, Cysal experienced great interest from national as well as international market-leading companies from various market segments with different utilization interests due to the manifold application possibilities of the raw material.
In addition to placing its own dipeptide end-products in specific market segments, Cysal aims at B2B marketing of the dipeptide raw material as well as sub-licensing the use of dipeptides in various application areas.